Absolute cardiovascular disease risk and lipid-lowering therapy among Aboriginal and Torres Strait Islander Australians

• Published in: Medical journal of Australia Vol. 209; no. 1; p. 35
• Main Authors: Calabria, Bianca, Korda, Rosemary J, Lovett, Raymond W, Fernando, Peter, Martin, Tanya, Malamoo, Leone, Welsh, Jennifer, Banks, Emily
• Format: Journal Article
• Language: English
• Published: Australia 02.07.2018
• Subjects: Adolescent; Adult; Aged; Algorithms; Australia - epidemiology; Cardiovascular Diseases - complications; Cardiovascular Diseases - drug therapy; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - prevention & control; Cross-Sectional Studies; Humans; Hyperlipidemias - complications; Hyperlipidemias - drug therapy; Hypolipidemic Agents - therapeutic use; Melanesia - epidemiology; Middle Aged; Oceanic Ancestry Group - statistics & numerical data; Risk Factors; Young Adult; Australia; Melanesia; Surveys and Questionnaires; Indigenous health; Population characteristics; Risk factors
• ISSN: 1326-5377
• DOI: 10.5694/mja17.00897

To quantify absolute cardiovascular disease (CVD) risk in Aboriginal and Torres Strait Islander people and their use of lipid-lowering therapies. Cross-sectional analysis of nationally representative data from 2820 participants aged 18-74 years who provided biomedical data for the National Aboriginal and Torres Strait Islander Health Measures Survey component of the 2012-13 Australian Aboriginal and Torres Strait Islander Health Survey. Prior CVD and use of lipid-lowering medications were ascertained at interview. 5-year absolute risk of a primary CVD event was calculated with the Australian National Vascular Disease Prevention Alliance algorithm, with categories low (< 10%), moderate (10-15%) and high risk (> 15%). Among participants aged 35-74 years, 9.6% (95% CI, 7.2-12.0%) had prior CVD; 15.7% (95% CI, 13.0-18.3%) were at high, 4.9% (95% CI, 3.3-6.6%) at moderate, and 69.8% (95% CI, 66.8-72.8%) at low absolute primary CVD risk. 82.6% of those at high primary risk were identified on the basis of clinical criteria. High primary absolute risk affected 1.1% (95% CI, 0.0-2.5%) of 18-24-year-olds, 4.7% (95% CI, 2.0-7.5%) of 25-34-year-olds, and 44.2% (95% CI, 33.1-55.3%) of 65-74-year-olds. Lipid-lowering therapy was being used by 52.9% (95% CI, 38.2-67.6%) of people aged 35-74 years with prior CVD and by 42.2% (95% CI, 30.5-53.8%) of those at high primary CVD risk. Absolute CVD risk is high among Aboriginal and Torres Strait Islander people, and most of those at high risk are undertreated. Substantial proportions of people under 35 years of age are at high risk, but are not targeted by current guidelines for absolute CVD risk assessment, compromising CVD prevention in this population.